BioMarin Pharmaceutical (BMRN)
(Real Time Quote from BATS)
$85.34 USD
+1.25 (1.49%)
Updated Jul 22, 2024 11:56 AM ET
4-Sell of 5 4
D Value D Growth D Momentum F VGM
BioMarin Pharmaceutical (BMRN) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$110.13 | $140.00 | $72.00 | 30.97% |
Price Target
Based on short-term price targets offered by 23 analysts, the average price target for BioMarin Pharmaceutical comes to $110.13. The forecasts range from a low of $72.00 to a high of $140.00. The average price target represents an increase of 30.97% from the last closing price of $84.09.
Analyst Price Targets (23)
Broker Rating
BioMarin Pharmaceutical currently has an average brokerage recommendation (ABR) of 1.64 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 25 brokerage firms. The current ABR compares to an ABR of 1.64 a month ago based on 25 recommendations.
Of the 25 recommendations deriving the current ABR, 17 are Strong Buy, representing 68% of all recommendations. A month ago, Strong Buy represented 68%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/BMRN.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 17 | 17 | 17 | 17 | 17 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 8 | 8 | 8 | 10 | 8 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.64 | 1.64 | 1.64 | 1.74 | 1.64 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
6/27/2024 | Wells Fargo Securities | Mohit Bansal | Strong Buy | Strong Buy |
6/5/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
5/31/2024 | Piper Sandler | Christopher Raymond | Strong Buy | Strong Buy |
5/22/2024 | Not Identified | Not Identified | Hold | Hold |
5/17/2024 | Not Identified | Not Identified | Strong Buy | Hold |
5/17/2024 | Robert W. Baird & Co. | Jack K Allen | Strong Buy | Hold |
5/14/2024 | Evercore Partners | Cory Kasimov | Not Available | Strong Buy |
4/25/2024 | Cantor Fitzgerald & Co | Olivia Brayer | Strong Buy | Strong Buy |
4/25/2024 | Scotiabank | George Farmer | Hold | Hold |
4/1/2024 | UBS | Eliana Merle | Strong Buy | Strong Buy |
4/1/2024 | Cowen & Co. | Philip M Nadeau | Strong Buy | Strong Buy |
4/1/2024 | BMO Capital Markets | Kostas Biliouris | Strong Buy | Strong Buy |
4/1/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
3/29/2024 | Goldman Sachs | Salveen Richter | Not Available | Strong Buy |
2/29/2024 | Canaccord Genuity | Whitney Ijem | Hold | Hold |
2/26/2024 | Not Identified | Not Identified | Hold | Hold |
2/23/2024 | Not Identified | Not Identified | Hold | Hold |
2/23/2024 | William Blair | Timothy F Lugo | Strong Buy | Strong Buy |
2/23/2024 | Not Identified | Not Identified | Hold | Hold |
11/28/2023 | Guggenheim Securities | Debjit Chattopadhyay | Strong Buy | Strong Buy |
11/2/2023 | SVB Securities | Joseph P Schwartz | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.64 |
ABR (Last week) | 1.64 |
# of Recs in ABR | 25 |
Average Target Price | $110.13 |
LT Growth Rate | 35.30% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 71 of 252 |
Current Quarter EPS Est: | 0.56 |